Amylin aims to raise over $200m
This article was originally published in Scrip
Amylin Pharmaceuticals is seeking over $203.1 million from the sale of 13 million shares of its common stock, having priced the shares at $15.62 each. The offering is expected to close on or around 13 March.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.